Today: 7 February 2026
Subscribe
Browse Category

NYSE:PFE News 3 January 2026 - 13 January 2026

Pfizer stock slips as CEO likens obesity drugs to Viagra; Metsera trials and Feb. 3 earnings in focus

Pfizer stock slips as CEO likens obesity drugs to Viagra; Metsera trials and Feb. 3 earnings in focus

New York, Jan 13, 2026, 15:07 EST — Regular session. Pfizer shares dipped 0.6% to $25.12 by mid-afternoon Tuesday, continuing a volatile stretch for the drugmaker as investors digested its recent comments on obesity treatments. The stock fluctuated between $24.98 and $25.42 during the session. The selling comes as CEO Albert Bourla pushes to sharpen Pfizer’s post-COVID growth narrative and justify its spending on new drugs. At Monday’s J.P. Morgan Healthcare Conference, Bourla likened the potential consumer demand for obesity meds to the early surge in Viagra sales and admitted Pfizer underestimated how quickly the “cash-pay” market—patients paying out of
13 January 2026
····
Pfizer stock slips as CEO says obesity cash-pay market is “almost like Viagra”

Pfizer stock slips as CEO says obesity cash-pay market is “almost like Viagra”

New York, Jan 13, 2026, 10:50 (EST) — Regular session Pfizer Inc (PFE) shares slipped about 0.7% to $25.10 Tuesday morning as investors digested the company’s latest obesity drug strategy unveiled at the J.P. Morgan Healthcare Conference in San Francisco. CEO Albert Bourla described the booming out-of-pocket weight-loss market as “almost like Viagra” now. Pfizer aims to launch 10 phase 3 trials for its Metsera obesity drugs by the end of 2026. The company has indicated it doesn’t expect revenue growth to resume until 2029. (Reuters) The obesity market has turned into a fierce arena for deals and capital spending
13 January 2026
·····
Pfizer stock dips as CEO says obesity-drug cash-pay demand looks “almost like Viagra”

Pfizer stock dips as CEO says obesity-drug cash-pay demand looks “almost like Viagra”

New York, January 12, 2026, 20:17 (EST) — Market closed. Pfizer Inc. shares fell on Monday after Chief Executive Albert Bourla said the cash-pay market for obesity drugs — where patients pay out of pocket — now works “almost like Viagra”, the erectile-dysfunction drug Pfizer launched in 1998. The company, which bought obesity developer Metsera in a deal valued at up to $10 billion and has said it does not expect to return to revenue growth until 2029, closed down 0.8% at $25.27. (Reuters) The remarks land as Pfizer tries to convince investors its post-COVID reset is more than cost
13 January 2026
·····
Tempus AI stock pops 12% premarket after $1.1 billion contracts update — what traders watch next

Tempus AI stock pops 12% premarket after $1.1 billion contracts update — what traders watch next

New York, Jan 12, 2026, 07:52 EST — Premarket Tempus AI shares climbed roughly 12%, reaching $74.34 in Monday’s premarket session. (Investing.com) The bid emerged amid a volatile morning for growth stocks, with Nasdaq 100 futures slipping close to 1% as investors digested fresh doubts over the Federal Reserve’s independence and prepared for earnings season to begin. (Reuters) Tempus projected full-year 2025 revenue around $1.27 billion in an SEC filing, marking an 83% jump from the previous year. That includes roughly 30% organic growth without Ambry. Diagnostics revenue hit about $955 million, soaring 111%, while data and applications brought in
12 January 2026
··········
Tempus AI stock jumps in premarket after $1.27 billion revenue preview, contract value tops $1.1 billion

Tempus AI stock jumps in premarket after $1.27 billion revenue preview, contract value tops $1.1 billion

New York, Jan 12, 2026, 05:29 EST — Premarket Tempus AI, Inc. shares were up about 11% in premarket trading on Monday after the company flagged strong preliminary 2025 results and reported record contract value with drugmakers. Tempus AI traded at $73.66 in premarket action, after ending Friday at $66.27. (google.com) The update lands as investors head into the annual J.P. Morgan Healthcare Conference week, when companies often try to reset expectations and pitch their 2026 story. Tempus has been a high-beta name in that mix, moving sharply on growth signals. For Tempus, the market focus has narrowed to two
12 January 2026
········
Pfizer stock price today: PFE ticks up after 340B court block as drug-pricing scrutiny returns

Pfizer stock price today: PFE ticks up after 340B court block as drug-pricing scrutiny returns

New York, Jan 8, 2026, 10:13 EST — Regular session Pfizer Inc shares rose 0.3% to $25.36 on Thursday after a U.S. appeals court blocked a Trump administration pilot that would have changed how safety-net hospitals pay for some medicines. The program covered the first 10 drugs heading into Medicare price negotiations, including Pfizer and Bristol Myers Squibb’s blood thinner Eliquis, and the American Hospital Association said it would have a “devastating effect.” Reuters Why it matters now is less about a single day’s trade and more about the plumbing of drug pricing. The 340B program requires manufacturers to sell
8 January 2026
····
Pfizer stock gains early as UBS starts coverage; Bayer mRNA lawsuit adds fresh risk

Pfizer stock gains early as UBS starts coverage; Bayer mRNA lawsuit adds fresh risk

New York, January 7, 2026, 09:54 EST — Regular session Pfizer shares rose about 0.9% to $25.67 in morning trade on Wednesday, even as investors weighed a new patent lawsuit tied to its COVID-19 vaccine and a cautious call from UBS. UBS began coverage of Pfizer with a Neutral rating and a $25 price target, pointing to what it described as revenue uncertainty as several big drugs face patent expirations in coming years. UBS estimated roughly $15 billion to $20 billion of annual revenue is exposed to loss of exclusivity — when patents expire and cheaper rivals move in —
7 January 2026
······
Pfizer stock in the spotlight: what to watch ahead of CEO Bourla’s JPM Healthcare Conference webcast

Pfizer stock in the spotlight: what to watch ahead of CEO Bourla’s JPM Healthcare Conference webcast

New York, January 5, 2026, 21:51 EST — Market closed Pfizer said it will webcast a discussion with Chief Executive Albert Bourla at the J.P. Morgan Healthcare Conference next week, putting the drugmaker’s 2026 reset back in focus. Pfizer shares finished Monday little changed, down 0.04% at $25.17. Pfizer The San Francisco gathering is a major kickoff for healthcare investing, and it comes as Pfizer tries to convince markets it can replace fading pandemic-era revenue. The company’s initial 2026 outlook, issued in December, came in below analysts’ estimates. JPMorgan Chase That timing matters because Pfizer is navigating lower sales of
6 January 2026
····
AbbVie stock slides 4% as pharma lags Wall Street rally — what investors watch next for ABBV

AbbVie stock slides 4% as pharma lags Wall Street rally — what investors watch next for ABBV

New York, Jan 5, 2026, 21:27 EST — Market closed AbbVie Inc shares closed down 4% on Monday at $220.18, lagging a Wall Street rally that pushed the Dow to a record high. The move mattered because drug and biotech names were among the day’s laggards as investors rotated into energy and financials after Venezuela headlines lifted oil-linked stocks. The NYSE Arca Pharmaceutical Index fell about 1.4% and the SPDR S&P Biotech ETF slid 1.1%, while the Health Care Select Sector SPDR ETF dipped 0.3%. Yahoo Finance AbbVie also put a near-term spotlight on its calendar, saying it will present
6 January 2026
·······
Pfizer stock today: PFE ends first 2026 session higher as pricing scrutiny returns and Feb. 3 results loom

Pfizer stock today: PFE ends first 2026 session higher as pricing scrutiny returns and Feb. 3 results loom

NEW YORK, Jan 3, 2026, 15:55 ET — Market closed Pfizer Inc (NYSE: PFE) shares last closed up 1.1% at $25.18 on Friday, after a weak finish to 2025. U.S. markets were closed on Saturday. The stock is starting 2026 with drug pricing back in focus, a recurring risk for big pharma that can weigh on sentiment. Drugmakers raised U.S. list prices on at least 350 branded medicines starting Jan. 1, with Pfizer leading with increases on about 80 drugs, including a 15% hike for its COVID vaccine Comirnaty, a report said. Becker’s Hospital Review The pricing debate lands as
3 January 2026
·····
Healthcare Stocks Today: XLV edges up as drugmakers raise U.S. list prices on 350 medicines

Healthcare Stocks Today: XLV edges up as drugmakers raise U.S. list prices on 350 medicines

NEW YORK, Jan 3, 2026, 13:21 ET — Market closed Drugmakers are lifting U.S. list prices on hundreds of medicines as 2026 begins, putting drug-pricing politics back in focus for healthcare investors. The sector finished higher in Friday’s session, the last U.S. trading day before the weekend. Drugmakers plan to raise U.S. prices on at least 350 branded medicines for 2026, including vaccines for COVID-19, RSV and shingles, as well as Pfizer’s cancer drug Ibrance, Reuters reported, citing data from healthcare research firm 3 Axis Advisors. The median list-price increase is about 4%, and the changes do not reflect rebates
3 January 2026
·······
Johnson & Johnson stock ticks up after $1.30 dividend; earnings next on the radar

Johnson & Johnson stock ticks up after $1.30 dividend; earnings next on the radar

NEW YORK, Jan 2, 2026, 20:13 ET — Market closed Johnson & Johnson shares ended Friday up 0.19% at $207.35 after the healthcare company said its board declared a $1.30-per-share cash dividend for the first quarter of 2026. Yahoo Finance The timing matters because investors entered 2026 with markets trying to stabilize after a late-December stretch that failed to deliver the usual year-end “Santa Claus” bounce. Wall Street’s focus is shifting back to interest-rate expectations and the next round of economic data. Reuters For income-focused investors, dividends can act as a buffer in volatile tape because they provide a cash
3 January 2026
······
1 2 3 4 5 6 … 10

Stock Market Today

Blackstone (BX) stock price rebounds after Sabre deal as jobs, CPI loom next week

Blackstone (BX) stock price rebounds after Sabre deal as jobs, CPI loom next week

7 February 2026
New York, February 6, 2026, 21:13 EST — Market closed. Blackstone Inc. (BX) shares closed up 2.25% at $129.69 on Friday, after a sharp drop the day before and a bruising week for the sector. The stock was last at $129.65 in late after-hours trading. (StockAnalysis) The swing matters because Blackstone sits in the crosshairs of a wider rethink of private-market managers. Investors have been quick to punish anything tied to leverage, credit risk and tech exposure, then just as quick to buy back when rates and risk appetite settle. That push-pull has been driven in part by an AI-linked
Verizon stock price snaps 7-day run as consumer chief exit sharpens focus on turnaround

Verizon stock price snaps 7-day run as consumer chief exit sharpens focus on turnaround

7 February 2026
Verizon shares fell 1.7% to $46.31 Friday, ending a seven-session rally and closing about 2.7% below Thursday’s one-year high. The dip follows news that consumer chief Sowmyanarayan Sampath will step down, with Alfonso Villanueva named interim head. Verizon has climbed 16% since January 29 amid strong subscriber growth and a $25 billion buyback plan.
Cisco stock jumps 3% near $85 as UBS sticks with Buy ahead of Feb. 11 earnings

Cisco stock jumps 3% near $85 as UBS sticks with Buy ahead of Feb. 11 earnings

7 February 2026
Cisco shares rose 3% to $84.82 Friday, nearing $85 ahead of fiscal Q2 results due Feb. 11. UBS maintained a Buy rating and $90 target, citing strong product order growth and data-center demand. Investors are watching AI-related spending and U.S. economic data that could affect rates. Peers Fortinet, CrowdStrike, and Palo Alto Networks also gained.
Go toTop